Status:

COMPLETED

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health

Lead Sponsor:

Duke University

Collaborating Sponsors:

Eggland's Best

Conditions:

Hypercholesterolemia

Hyperlipidemia

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

The objective of the study is to assess the effect of fortified eggs (compared to a non-egg supplemented diet) and intermittent fasting (IF) (compared to a usual care diet) on biomarker profile at 4 m...

Eligibility Criteria

Inclusion

  • ≥ 50 years of age AND
  • At least one of the following two criteria:
  • Prior cardiovascular event (myocardial infarction, coronary revascularization or ischemic stroke) OR
  • 2 cardiovascular risk factors including: 1) Diabetes mellitus (Defined as taking a medication for diabetes OR HgbA1c ≥6.5% within the prior 18 months; patients with diabetes may be treated with medications that are not associated with hypoglycemia such as metformin, thiazolidinediones (TZDs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium glucose co-transporter 2 (SGLT2) inhibitors and/or dipeptidyl peptidase-4 (DPP-4) inhibitors, 2) Body mass index (BMI) ≥ 30 kg/m2, 3) Hypertension (Defined as taking blood pressure lowering medications OR systolic BP \> 140mmHg at screening OR diastolic BP \> 90mmHg at screening), 4) Dyslipidemia (Defined as taking lipid lowering medication OR LDL ≥130 OR HDL \<50 for women OR HDL \<40 for men OR triglycerides ≥150), or 5) Chronic kidney disease (Defined as eGFR \<60 on most recent laboratory assessment within prior 18 months)
  • Signed informed consent

Exclusion

  • Known allergy or intolerance to eggs
  • Patients with diabetes who are on insulin or insulin secretagogues (e.g., sulfonylureas and meglitinides)
  • Recent cardiovascular event (MI, stroke, HF hospitalization) within the past 30 days
  • Planned initiation/change in lipid therapy within the next 4 months
  • Current daily use of any supplements or multivitamins containing Vitamin B2 (riboflavin), Vitamin B12, Vitamin D, Vitamin E, or selenium or planned initiation within the next 4 months (current users need a 1-month washout period off supplement prior to eligibility)
  • Inability or unwillingness to comply with the study requirements
  • History of heart transplant or left ventricular assist device
  • Pregnant or nursing women
  • Malignancy or other non-cardiac condition limiting life expectancy to \<4 months
  • Consumption of \> 2 eggs per week (this does not include eggs contained within other foods)
  • Ongoing or recent (prior 30 days) participation in another interventional study

Key Trial Info

Start Date :

January 6 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 13 2022

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT04673721

Start Date

January 6 2021

End Date

December 13 2022

Last Update

January 23 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Duke University Health System

Durham, North Carolina, United States, 27710

PROSPective Evaluation of Fortified Eggs Related to Improvement in The Biomarker Profile for Your Health | DecenTrialz